Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.64 |
| ▸ | MAOA | P21397 | 3/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12342703 | 1.00 | TAAR1 (0.64) | TAAR1SLC6A2SLC6A3MAOASLC6A4 | |
| SCHEMBL9468040 | 0.93 | TAAR1 (0.57) | TAAR1SLC6A2SLC6A3MAOASLC6A4 | |
| SCHEMBL10872755 | 0.89 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A3MAOASLC6A4 | |
| SCHEMBL10872752 | 0.89 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A3MAOASLC6A4 | |
| SCHEMBL4624045 | 0.82 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A3MAOASLC6A4 | |
| SCHEMBL10775150 | 0.82 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A3MAOASLC6A4 | |
| SCHEMBL27852110 | 0.82 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A3MAOASLC6A4 | |
| SCHEMBL29059546 | 0.82 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A3MAOASLC6A4 | |
| SCHEMBL19395992 | 0.82 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A3MAOASLC6A4 | |
| SCHEMBL27560699 | 0.82 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A3MAOASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770514-B2 | Tamper-resistant pharmaceutical dosage forms | ExxPharma Therapeutics LLC (US) | 2017-09-26 | — | — | US | claimed |
| US-20150064250-A1 | Tamper-Resistant Pharmaceutical Dosage Forms | ExxPharma Therapeutics LLC (US) | 2015-03-05 | — | — | US | claimed |
| EP-3271715-B1 | METHODS FOR ANALYTE DETECTION AND QUANTIFICATION USING THRESHOLD ANALYTE CALIBRATION | WATERS TECHNOLOGIES CORP (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20200282061-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS | LIPOCINE INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-20180264117-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS | LIPOCINE INC. (US) | 2018-09-20 | — | — | US | disclosed |
| US-10010620-B2 | Tamper-resistant pharmaceutical dosage forms and process for making same | ExxPharma Therapeutics LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180125979-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS | LIPOCINE INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9770514-B2 | Tamper-resistant pharmaceutical dosage forms | ExxPharma Therapeutics LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170029366-A1 | INHIBITORS OF HISTONE LYSINE SPECIFIC DEMETHYLASE (LSD1) AND HISTONE DEACETYLASES (HDACS) | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-02 | — | — | US | disclosed |
| US-20160184435-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS | LIPOCINE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160175454-A1 | Tamper-Resistant Pharmaceutical Dosage Forms and Process for Making Same | NEUROCRINE BIOSCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20040115287-A1 | Hydrophobic active agent compositions and methods | LIPOCINE, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20030235595-A1 | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent | LIPOCINE, INC. | 2003-12-25 | — | — | US | disclosed |
| US-20030236236-A1 | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs | LIPOCINE INC. | 2003-12-25 | — | — | US | disclosed |
| US-5980882-A | A SOLID OR A GEL MEDICINE COMPRISING DEXTROMETHORPHAN, CODEINE, MORPHINE, HYDRCODONE, PSEUDOEPHEDRINE, OR PHENYLPROPANOLAMINE AND COMPLEXED WITH CHELATING AGENT SELECTED FROM EDTA OR A SALT OF EDTA; STORAGE STABILITY | MEDEVA PHARMACEUTICALS MANUFACTURING (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0911039-A2 | Drug-resin complexes stabilized by chelating agents | Medeva Pharmaceutical Manufacturing, Inc. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0101381-B1 | ANOREXIC TRIFLUOROMETHYL PHENYL TETRAHYDROPYRIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI S.A. (FR) | 1985-12-04 | — | — | EP | disclosed |
| EP-0060176-B1 | SUBSTITUTED TRIFLUOROMETHYLPHENYLTETRAHYDROPYRIDINES HAVING ANORECTIC ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI S.A. (FR) | 1985-01-02 | — | — | EP | disclosed |
| EP-0101381-A1 | Anorexic trifluoromethyl phenyl tetrahydropyridines, process for their preparation and pharmaceutical compositions containing them | SANOFI S.A. (FR) | 1984-02-22 | — | — | EP | disclosed |
| EP-0060176-A1 | Substituted trifluoromethylphenyltetrahydropyridines having anorectic activity, their preparation and pharmaceutical compositions containing them | SANOFI S.A. (FR) | 1982-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030235595-A1 | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent | LIPA, LIPC, CETP | TAAR1 2789/4885SLC6A2 1083/4885SLC6A3 2405/4885 |
| US-20170029366-A1 | INHIBITORS OF HISTONE LYSINE SPECIFIC DEMETHYLASE (LSD1) AND HISTONE DEACETYLASES (HDACS) | KDM1B, KDM2A, EHMT2 | TAAR1 1135/4885SLC6A2 616/4885SLC6A3 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.